血管活性药物使用对机械通气患者ICU获得性衰弱的影响
本研究为一项随机临床试验的二次分析,纳入172例机械通气患者,比较早期职业与物理治疗vs常规治疗,主要终点为出院时ICU获得性衰弱。由对分组不知情的治疗师进行床旁肌力测试评估ICU获得性衰弱。Logistic回归显示,使用血管活性药物增加ICU获得性衰弱风险(OR 3.2,P=0.01),独立于其他已知危险因素;用药天数(OR 1.35,P=0.004)和去甲肾上腺素累积剂量(OR 1.01,P=0.02)亦独立相关,而血管加压素或去氧肾上腺素无此关联。作者认为需前瞻性试验进一步评估该关系。
要点
- 机械通气患者使用血管活性药物与ICU获得性衰弱独立相关:OR 3.2(P=0.01),校正其他已知危险因素后仍显著。
- 血管活性药物使用天数每增加1天,ICU获得性衰弱风险独立增加:OR 1.35(P=0.004)。
- 去甲肾上腺素累积剂量(μg/kg/d)与ICU获得性衰弱独立相关:OR 1.01(P=0.02)。
- 血管加压素或去氧肾上腺素与ICU获得性衰弱无独立关联(原文仅报告去甲肾上腺素、血管加压素、去氧肾上腺素的结果)。
- 该研究为随机临床试验的二次分析,作者认为需前瞻性试验进一步评估血管活性药物与ICU获得性衰弱的关系。
适用人群与场景
- 纳入机械通气患者,共172例,来源于一项比较早期职业与物理治疗vs常规治疗的随机临床试验。
诊断标准与关键阈值
- ICU获得性衰弱通过治疗师床旁肌力测试评估,治疗师对研究分组不知情,评估时间为出院时。
研究设计与关键结果
- 研究类型:随机临床试验的二次分析;样本量172例机械通气患者;干预为早期职业与物理治疗vs常规治疗;主要终点为出院时ICU获得性衰弱。
- 使用血管活性药物增加ICU获得性衰弱风险:OR 3.2(P=0.01),独立于所有其他已知衰弱危险因素。
- 血管活性药物使用天数(天)与ICU获得性衰弱独立相关:OR 1.35(P=0.004)。
- 去甲肾上腺素累积剂量(μg/kg/d)与ICU获得性衰弱独立相关:OR 1.01(P=0.02);血管加压素或去氧肾上腺素无独立关联。
证据类型、等级与局限
- 证据类型:随机临床试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在机械通气患者中,使用血管活性药物、用药天数及去甲肾上腺素累积剂量与ICU获得性衰弱独立相关,提示临床医生应关注接受血管活性药物治疗患者的衰弱风险。
- 作者认为,需前瞻性试验进一步评估血管活性药物与ICU获得性衰弱的关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vasoactive medications are commonly used in the treatment of critically ill patients, but their impact on the development of ICU-acquired weakness is not well described. The objective of this study is to evaluate the relationship between vasoactive medication use and the outcome of ICU-acquired weakness.
METHODS: This is a secondary analysis of mechanically ventilated patients (N = 172) enrolled in a randomized clinical trial of early occupational and physical therapy vs conventional therapy, which evaluated the end point of ICU-acquired weakness on hospital discharge. Patients underwent bedside muscle strength testing by a therapist blinded to study allocation to evaluate for ICU-acquired weakness. The effects of vasoactive medication use on the incidence of ICU-acquired weakness in this population were assessed.
RESULTS: On logistic regression analysis, the use of vasoactive medications increased the odds of developing ICU-acquired weakness (odds ratio [OR], 3.2; P = .01) independent of all other established risk factors for weakness. Duration of vasoactive medication use (in days) (OR, 1.35; P = .004) and cumulative norepinephrine dose (μg/kg/d) (OR, 1.01; P = .02) (but not vasopressin or phenylephrine) were also independently associated with the outcome of ICU-acquired weakness.
CONCLUSIONS: In mechanically ventilated patients enrolled in a randomized clinical trial of early mobilization, the use of vasoactive medications was independently associated with the development of ICU-acquired weakness. Prospective trials to further evaluate this relationship are merited.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01777035; URL: www.clinicaltrials.gov.
参考来源
- Wolfe KS, Patel BK, MacKenzie EL, et al. Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients. Chest. 2018. PMID: 30217640. doi:10.1016/j.chest.2018.07.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。